Zorana Maravic, CEO, Digestive Cancers Europe took part in the Global Colon Cancer Association’s Third Annual Virtual Global Colorectal Cancer Congress on March 31 – April 1, 2022. The theme of the event was “ […]

We are very pleased to give a warm and hearty welcome to Codice Viola into our Digestive Cancers Europe network of Members. They are an Italian pancreatic cancer patient organisation working to improve the overall […]

March 21 is Anal Cancer Awareness Day. Anal cancer is a rare cancer on the rise. In the EU 9.249 men and women were newly diagnosed with this cancer, in 2020.1

The major risk factor for anal cancer is human […]

March 22 is Lynch Syndrome Awareness Day. Lynch Syndrome is the most common inherited cancer syndrome in the world, with an estimation of 1 in 370 people carrying the genetic mutation.1 Lynch Syndrome is […]

As a service to our Members Organisations, all materials that Digestive Cancers Europe produces are available to be translated and shared as widely as possible in local languages. To support this we are working on […]

The two most common types of oesophageal cancer are squamous cell carcinoma (OSCC) and adenocarcinoma (OAC). The majority of oesophageal cancers belong to the OSCC sub-type, accounting for more than 85% of all […]

Fuel for new and improved cancer screening programmes in Europe was released at the beginning of March in the form of two reports, one from the Science Advice for Policy by European Academies (SAPEA) and the […]

In light of the current situation, Digestive Cancers Europe would like to highlight its concern at what is unfolding in the Ukraine and the human suffering that is being caused. We want to underline that we are […]

Every year, 500.000 citizens in Europe are diagnosed with colorectal cancer, with 240.000 people a year sadly passing away from the disease. Patients who are diagnosed early (stage I), have a 90% chance of […]

This article was kindly contributed by Katlijn Sanctorum (pictured below) of the Belgian Familial Adenomatous Polyposis Association (FAPA).

Patients with hereditary tumor syndromes often receive a late […]

A study published in the European Journal of Cancer has shown that a DNA test prior to chemotherapy with the drug Irinotecan can guide dosing and thus prevent serious side effects. Irinotecan is used in patients […]

DiCE CEO, Zorana Maravic presented the view of the digestive cancer patient community at the February event “15 Years of Biosimilars: Improving Equitable Access to Essential and Affordable Biologic Medicines in […]

The EU4Health 2022 work programme was officially launched by the European Commission on January 14. It is the European Union’s response to the current public health emergency aimed at making a significant c […]

Teams of researchers from Spain have identified a new viable marker for early diagnosis in the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma. The study is published in the journal […]

Join us in our annual campaign for Oesophageal Cancer Awareness Month during April.

Every year an estimated 53.000 people in Europe receive the difficult diagnosis of having oesophageal cancer. A cancer that […]

How does one manage the emotional impact after the announcement of a cancer? This is the question to which ‘LEA – Listen Explain & Act’ program, a project launched by the Servier laboratory, in partnership with […]

The European Institutions announced in 2021 a series of initiatives in the field of health, particularly relating to the EU Beating Cancer Plan, that will shape DiCE policy initiatives in the next […]